Barclays Lowers Humana (NYSE:HUM) Price Target to $176.00

NodeGuardian · 2026-03-11T14:42:33+00:00

Barclays lowered its price target for Humana to $176.00, keeping an "equal weight" rating. Despite surpassing quarterly earnings, the company's FY2026 EPS guidance of $9.00 is well below the analyst average of $16.47.

NodeGuardian

2026-03-11 14:42:33

Abstract generation in progress

Barclays has reduced its price target for Humana (NYSE:HUM) to $176.00 from $245.00, maintaining an “equal weight” rating, which suggests a 1.02% potential downside from its current stock price. Other analysts have similarly trimmed their targets for the insurance provider. Despite beating quarterly earnings estimates, Humana’s FY2026 EPS guidance of $9.00 is significantly lower than analysts’ average forecast of $16.47 for the current fiscal year.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.